Sana Biotechnology Appoints Brian Piper as Executive Vice President, Chief Financial Officer

summarizeSummary

Sana Biotechnology announced the appointment of Brian Piper as its new Executive Vice President, Chief Financial Officer, bringing significant financial and operational expertise to the company.

check_boxKey Events

• New CFO Appointment

  Brian Piper, M.B.A., joined Sana Biotechnology as Executive Vice President, Chief Financial Officer, and Treasurer, effective February 17, 2026.

• CEO Relinquishes Acting CFO Role

  Steven D. Harr, President and CEO, ceased serving as acting Principal Financial Officer immediately prior to Mr. Piper's commencement date.

• Compensation Package Detailed

  Mr. Piper will receive an annual base salary of $515,000, a target annual bonus of 40% of his base salary, an option to purchase 900,000 shares, and 200,000 restricted stock units (RSUs).

• Extensive Industry Experience

  Mr. Piper's background includes CFO roles at Scorpion Therapeutics, Antares Therapeutics, Prelude Therapeutics, and Aevi Genomic Medicine, along with 12 years at Shire Pharmaceuticals.

auto_awesomeAnalysis

Sana Biotechnology has appointed Brian Piper as its new Executive Vice President, Chief Financial Officer, filling a critical leadership role previously held on an acting basis by the CEO. Piper brings extensive biopharmaceutical financial and operational experience, including prior CFO roles at other biotech companies. His appointment is strategically important for Sana as it advances its clinical programs, particularly with upcoming data for its type 1 diabetes and in vivo CAR T platforms. A dedicated and experienced CFO is crucial for capital formation, disciplined capital allocation, and optimizing long-term value creation in the capital-intensive life sciences sector.